Trial Profile
A 6-week multicenter, randomized, double-blind, placebo-controlled, parallel group effficacy trial of 2 different dose regimens of lumiracoxib (100 mg bid and 200 mg od)in patients with primary knee osteoarthritis using naproxen 500 mg bid as a positive control
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 21 Jun 2011
Price :
$35
*
At a glance
- Drugs Lumiracoxib (Primary) ; Naproxen
- Indications Osteoarthritis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novartis
- 21 Jun 2011 New trial record